🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. CABOMETYX 40 mg film-coated tablets, CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Fondazione Telethon ETS

    Non small-cell lung cancer

    phase 2 small molecule active

    1 trial

  2. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  3. CABOZANTINIB

    Fondazione Telethon ETS

    Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.

    phase 2 small molecule active

    1 trial

  4. CABOZANTINIB, CABOZANTINIB, LANREOTIDE, CABOZANTINIB

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

  5. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  6. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  7. CANNABIDIOL, DRONABINOL

    Disc Medicine

    Patients with untreatable hepatocellulare carcinoma

    phase 2 small molecule active

    1 trial

  8. CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , DURVALUMAB , OXALIPLATIN

    Disc Medicine

    Locally advanced rectal cancer

    phase 2 small molecule active

    1 trial

  9. CAPECITABINE , OXALIPLATIN

    Disc Medicine

    Patients with early-stage rectal cancer (defined as early rectal cancer cT1-3abN0M0 or early-intermediate rectal cancer cT1-3abN1(≤3 nodes ≤8mm)M0

    phase 2 small molecule active

    1 trial

  10. CAPECITABINE , VALPROIC ACID

    Fondazione Telethon ETS

    low- risk rectal cancel

    phase 2 small molecule active

    1 trial

  11. CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  12. CAPECITABINE, CAPECITABINE, NUBEQA 300 mg film-coated tablets

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  13. CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  14. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. CAPECITABINE, Lonsurf 15 mg/6.14 mg film-coated tablets, FOLINIC ACID, FLUOROURACIL, OXALIPLATIN, NIVOLUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, LEVOLEUCOVORIN

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  17. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, IRINOTECAN, CAPECITABINE

    Fondazione Telethon ETS

    Colon cancer

    phase 2 small molecule active

    1 trial

  18. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  19. CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  20. CARBOPLATIN, ATEZOLIZUMAB, ETOPOSIDE, Ifinatamab deruxtecan

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  21. CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  22. CARBOPLATIN, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, ETOPOSIDE, CISPLATIN, Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil Accord 250 mg capsules, Inflectra 100 mg powder for concentrate for solution for infusion, TAGRISSO 80 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for sol

    AstraZeneca AB

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. CARBOPLATIN, ETOPOSIDE, CARBOPLATIN, ATEZOLIZUMAB, ABBV-706

    AbbVie Deutschland GmbH & Co. KG

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. CARBOPLATIN, Mirvetuximab Soravtansine, BEVACIZUMAB

    AbbVie Deutschland GmbH & Co. KG

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources